Combination Therapy for High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) with and without BCG Pretreatment

被引：0
|
作者：
Rexer, Heidrun [1 ]
Grimm, Marc-Oliver [2 ]
Ohlmann, Carsten-H. [3 ]
机构：
[1] AUO Geschaftsstelle, Bad Herrenalb, Germany
[2] Univ Klinikum Jena, Klin & Poliklin Urol, Jena, Germany
[3] Deutsch Krebsgesell eV, Arbeitsgemeinschaft Urol Onkol, Berlin, Germany
来源：
AKTUELLE UROLOGIE | 2024年 / 55卷 / 05期
关键词：
D O I：
10.1055/a-2365-9589
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Randomized, active-controlled phase III clinical trial to evaluate the efficacy and safety of pembroli-zumab (MK-3475) in combination with Bacillus Calmette-Gu & eacute;rin (BCG) in patients with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) that persists or relapses after induction therapy with BCG and for BCG-naive patients (KEYNOTE-676)-AB 64/18 of the AUO
引用
收藏
页码：412 / 413
页数：2
相关论文
共 50 条
  • [1] Combination therapy in high-risk non-muscle invasive bladder cancer (HR-NMIBC) with and without BCG prior treatment
    Rexer, H.
    Ohlmann, C. -H.
    Grimm, M. -O.
    UROLOGIE, 2023, 62 (03): : 338 - 339
  • [2] Combination Therapy for Patients with High-Risk non-muscle-invasive Bladder Cancer (HR-NMIBC) Randomized Phase III verum-controlled clinical Trial for Evaluating the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Patients with High-Risk non-muscle-invasive Bladder Cancer (HR-NMIBC) that persists or relapses following Induction Therapy with BCG (KEYNOTE-676) - AB 64/18 of the AUO
    Rexer, H.
    Ohlmann, C-H.
    Grimm, M-O.
    UROLOGE, 2019, 58 (08): : 991 - 992
  • [3] TRUCE04: A Phase II clinical trial of RC48 for High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) 24)
    Hu, H.
    Guo, S.
    Shen, C.
    Huang, S.
    Zhao, G.
    Zhang, Z.
    Wu, Z.
    Chen, H.
    Chen, H.
    Liang, S.
    Yuanjie, N.
    EUROPEAN UROLOGY, 2024, 85 : S1711 - S1711
  • [4] Is there a role for urine cytology following BCG therapy for non-muscle-invasive bladder cancer (NMIBC)?
    Prattley, Sarah
    Jarvis, Ruth
    Featherstone, Jon
    Narahari, Krishna
    Varma, Murali
    Hughes, Owen
    Kynaston, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [5] Practice patterns of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world Canadian practice.
    Gotto, Geoffrey T.
    Alimohamed, Nimira S.
    Kulkarni, Girish S.
    Black, Peter C.
    Kassouf, Wassim
    Sridhar, Srikala S.
    Kokorovic, Andrea
    Eigl, Bernhard J.
    Blais, Normand
    Lalani, Aly-Khan A.
    Osborne, Brendan J. W.
    Wallis, Christopher J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
    Rajan Veeratterapillay
    Rakesh Heer
    Mark I. Johnson
    Raj Persad
    Christian Bach
    Current Urology Reports, 2016, 17
  • [7] Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer
    Catto, J. W. F.
    Tran, B.
    Roupret, M.
    Gschwend, J. E.
    Loriot, Y.
    Nishiyama, H.
    Redorta, J. P.
    Daneshmand, S.
    Hussain, S. A.
    Cutuli, H. J.
    Procopio, G.
    Guadalupi, V.
    Vasdev, N.
    Naini, V.
    Crow, L.
    Triantos, S.
    Baig, M.
    Steinberg, G.
    ANNALS OF ONCOLOGY, 2024, 35 (01) : 98 - 106
  • [8] Experimental and New Approaches for Bladder Preservation in Intermediate and High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
    Avilez, Natalia
    Capibaribe, Diego M.
    Reis, Leonardo
    RESEARCH AND REPORTS IN UROLOGY, 2024, 16 : 89 - 113
  • [9] Exploratory biomarkers to predict the benefit of adding mitomycin (MM) to BCG as intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC)
    Law, Ngie Chang
    Redfern, Andrew
    Spalding, Lisa
    McCombie, Stephen
    Hawks, Cynthia
    Swarbrick, Nicole
    Stockler, Martin
    Davis, Ian
    Hayne, Dickon
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 68 - 69
  • [10] High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG Shortage
    Veeratterapillay, Rajan
    Heer, Rakesh
    Johnson, Mark I.
    Persad, Raj
    Bach, Christian
    CURRENT UROLOGY REPORTS, 2016, 17 (09)
12345